CRISPR Cas9 Mediated Caveolin-1 Knockout Sensitizes Radioresistant Non-Small Cell Lung Cancer

Samanta, Sukhen; Mahmood, Javed; Creed, Michael; Alexander, A.; Soman, S.; Shukla, Hem D.; Eley, John G.; Kingsbury, Tami J.; Sawant, Amit; Vujašković, Željko

doi:10.1016/j.ijrobp.2018.07.678

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings clarified that Cav-1 could be considered as a new prognostic biomarker to predict resistance to radiotherapy in NSCLC. 85 Recent studies have indicated that paraoxonase 2 (PON2), a lactonase/arylesterase with antioxidant properties, is significantly overexpressed in cancer tissues of NSCLC patients. PON2 overexpression has been shown to contribute to the resistance of NSCLC cells to chemotherapeutic agents and CRISPR/Cas-mediated PON2 downregulation to suppress the proliferation of these cells.…”

Section: Crispr-cas9 and Lc Drug Resistancementioning

confidence: 99%

CRISPER/CAS System, a Novel Tool of Targeted Therapy of Drug-resistant Lung Cancer

et al. 2021

View full text Add to dashboard Cite

Lung cancer (LC) is the most common cause of cancer-related death worldwide. Patients with LC are usually diagnosed at advanced phases. Five-year survival rate in LC patients is approximately 16%. Despite decades of research on LC treatments, clinical outcomes are still very poor, necessitating to develop novel technologies to manage the disease. Considering the role of genetic and epigenetic changes in oncogenes and tumor-suppressor genes in cancer progression, gene therapy provides a hot spot in cancer treatment research. Gene therapy offers less side effects compared to conventional methods such as chemotherapy. Unlike the traditional approaches of gene therapy that have temporary effects, using genetic modification tools can offer persistent cure. Over the past a few years, many studies have effectively used the CRISPR–Cas9 approach to modify gene expression in cells. This system is applied to induce site-specific mutagenesis and epigenetic modifications and regulate gene expression. In this review, we discuss recent applications of the CRISPR–Cas9 technology in treating LC.

show abstract

Section: Crispr-cas9 and Lc Drug Resistancementioning

confidence: 99%